Evidence map›Paper›PMID 39408877›Full record

ReviewInternational journal of molecular sciences2024

TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis.

Razan Orfali, Ali AlFaiz, Madhawi Alanazi, Rahaf Alabdulsalam, Meaad Alharbi, Yara Alromaih, Ismail Dallak, Marah Alrahal, Abdulaziz Alwatban, Reem Saud

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Razan OrfaliResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.ORCID 0000-0002-0584-4013
Ali AlFaizResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Madhawi AlanaziResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Rahaf AlabdulsalamResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Meaad AlharbiResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Yara AlromaihResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Ismail DallakKing Abdulaziz Medical City, Jeddah 9515, Saudi Arabia.
Marah AlrahalResearch Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 12231, Saudi Arabia.
Abdulaziz AlwatbanCollege of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.
Reem SaudGeneral Education Department, Dar Al-Hikmah University, Jeddah 22246, Saudi Arabia.

Funding

King Fahad medical city 023-012
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorTRPV Cation ChannelsAnimalsHumansCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorTRPV4 protein, humanTRPV Cation Channelscystic fibrosislungsmotile ciliamucociliary clearanceTRPV4 channels

Identifiers

PMID39408877
PMCPMC11476765

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.